Expression of Toll-Like Receptor 4 Contributes to Corneal Inflammation in Experimental Dry Eye Disease

Hyun Lee

Takaaki Hattori

Eun Park

William Stevenson

Sunil Chauhan

Reza Dana

Supplementary Material

Supplemental Data:

Click here to view.

From the 1Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts and the

2Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

Corresponding author: Reza Dana, Schepens Eye Research Institute, 20 Staniford Street, Boston, MA 02114; ude.dravrah.snepehcs@anad.azer.

Received 2012 Jan 20; Revised 2012 Jun 29; Accepted 2012 Jul 9.

Abstract

Purpose.

To investigate the corneal expression of toll-like receptor (TLR) 4 and determine its contribution to the immunopathogenesis of dry eye disease (DED).

Methods.

Seven to 8-week-old female C57BL/6 mice were housed in a controlled environment chamber and administered scopolamine to induce experimental DED. Mice received intravenous TLR4 inhibitor (Eritoran) to block systemic TLR4-mediated activity. The expression of TLR4 by the corneal epithelium and stroma was evaluated using real-time polymerase chain reaction and flow cytometry. Corneal fluorescein staining (CFS) was performed to evaluate clinical disease severity. The corneal expression of proinflammatory cytokines (IL-1β, IL-6, TNF, and CCL2), corneal infiltration of CD11b^{antigen-presenting cells, and lymph node frequency of mature MHC-II}^CD11b^{cells were assessed.}

Results.

The epithelial cells of normal corneas expressed TLR4 intracellularly; however, DED significantly increased the cell surface expression of TLR4. Similarly, flow cytometric analysis of stromal cells revealed a significant increase in the expression of TLR4 proteins by DED-induced corneas as compared with normal corneas. DED increased the mRNA expression of TLR4 in corneal stromal cells, but not epithelial cells. TLR4 inhibition decreased the severity of CFS and significantly reduced the mRNA expression of IL-1β, IL-6, and TNF. Furthermore, TLR4 inhibition significantly reduced the corneal infiltration of CD11b^{cells and the lymph node frequency of MHC-II}^CD11b^cells.

Conclusions.

These results suggest that DED increases the corneal expression of TLR4 and that TLR4 participates in the inflammatory response to ocular surface desiccating stress.

Abstract

Click here to view.

Footnotes

Supported in part by National Eye Institute/National Institutes of Health Grant EY-20889.

Disclosure: H.S. Lee, Eisai Research Institute (R); T. Hattori, None; E.Y. Park, None; W. Stevenson, None; S.K. Chauhan, None; R. Dana, None

Footnotes

References

1. Chauhan SK, El Annan J, Ecoiffier T, et al Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009;182:1247–1252
2. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90–100
3. Lemp MA, Baudouin C, Baum J, et al The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:75–92 [[PubMed]
4. Luo L, Li DQ, Doshi A, et al Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45:4293–4301 [[PubMed]
5. Luo L, Li DQ, Pflugfelder SC. Hyperosmolarity-induced apoptosis in human corneal epithelial cells is mediated by cytochrome c and MAPK pathways. Cornea. 2007;26:452–460 [[PubMed]
6. Stern ME, Gao J, Schwalb TA, et al Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609–2614 [[PubMed]
7. Yoon KC, De Paiva CS, Qi H, et al Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci. 2007;48:2561–2569 [[PubMed]
8. Chotikavanich S, de Paiva CS. Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50:3203–3209
9. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest. 2003;111:1571–1578
10. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499–511 [[PubMed]
11. Hornung V, Rothenfusser S, Britsch S, et al Quantitative expression of Toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168:4531–4537 [[PubMed]
12. Ueta M, Nochi T, Jang MH, et al Intracellularly expressed TLR2s and TLR4s contribution to an immunosilent environment at the ocular mucosal epithelium. J Immunol. 2004;173:3337–3347 [[PubMed]
13. Sun Y, Pearlman E. Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564). Invest Ophthalmol Vis Sci. 2009;50:1247–1254
14. Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev. 2000;173:89–97 [[PubMed]
15. Zhang J, Kumar A, Wheater M, Yu FS. Lack of MD-2 expression in human corneal epithelial cells is an underlying mechanism of lipopolysaccharide (LPS) unresponsiveness. Immunol Cell Biol. 2009;87:141–148
16. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–376 [[PubMed]
17. Shimamoto A, Chong AJ, Yada M, et al Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006;114(suppl 1):1270–1274 [[PubMed]
18. Kerfoot SM, Long EM, Hickey MJ, et al TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol. 2004;173:7070–7077 [[PubMed]
19. Barabino S, Shen L, Chen L, et al The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005;46:2766–2771 [[PubMed]
20. Lee HS, Chauhan SK, Okanobo A, Nallasamy N, Dana R. Therapeutic efficacy of topical Epigallocatechin gallate in murine dry eye. Cornea. 2011;30:1465–1472
21. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221–232 [[PubMed]
22. Schlereth S, Lee HS, Khandelwal P, Saban DR. Blocking CCR7 at the ocular surface impairs the pathogenic contribution of dendritic cells in allergic conjunctivitis. Am J Pathol. 2012;180:2351–2360 [[PubMed]
23. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252 [[PubMed]
24. Jurewicz M, Takakura A, Augello A, et al Ischemic injury enhances dendritic cell immunogenicity via TLR4 and NF-kappa B activation. J Immunol. 2010;184:2939–2948 [[PubMed]
25. Goyal S, Chauhan SK, Zhang Q, et al Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. Arch Ophthalmol. 2009;127:882–887 [[PubMed]
26. Ecoiffier T, El Annan J, Rashid S, Schaumberg D, Dana R. Modulation of integrin alpha4beta1 (VLA-4) in dry eye disease. Arch Ophthalmol. 2008;126:1695–1699 [[PubMed]
27. Goyal S, Chauhan SK, Dana R, et al Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?Arch Ophthalmol. 2010;128:819–824
28. Schaumburg CS, Siemasko KF, de Paiva CS, et al Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis. J Immunol. 2011;187:3653–3662 [[PubMed]
29. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6:823–835 [[PubMed]
30. Shen H, Tesar BM, Walker WE, Goldstein DR. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J Immunol. 2008;181:1849–1858
31. Dieu MC, Vanbervliet B, Vicari A, et al Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998;188:373–386
32. Kumar A, Yu FS. Toll-like receptors and corneal innate immunity. Curr Mol Med. 2006;6:327–337
33. Gioannini TL, Teghanemt A, Zhang D, et al Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA. 2004;101:4186–4191
34. Song PI, Abraham TA, Park Y, et al The expression of functional LPS receptor proteins CD14 and toll-like receptor 4 in human corneal cells. Invest Ophthalmol Vis Sci. 2001;42:2867–2877 [[PubMed]
35. Blais DR, Vascotto SG, Griffith M, Altosaar I. LBP and CD14 secreted in tears by the lacrimal glands modulate the LPS response of corneal epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:4235–4244 [[PubMed]
36. Tsukamoto H, Fukudome K, Takao S, Tsuneyoshi N, Kimoto M. Lipopolysaccharide-binding protein-mediated Toll-like receptor 4 dimerization enables rapid signal transduction against lipopolysaccharide stimulation on membrane-associated CD14-expressing cells. Int Immunol. 2010;22:271–280 [[PubMed]
37. Jiang Q, Akashi S, Miyake K, Petty HR. Cutting edge: lipopolysaccharide induces physical proximity between CD14 and Toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-κB. J Immunol. 2000;165:3541–3544 [[PubMed]
38. Lee JH, Cho ML, Kim JI, et al Interleukin 17 (IL-17) increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1beta and IL-6 production in autoimmune arthritis. J Rheumatol. 2009;36:684–692 [[PubMed]
39. Abreu MT, Arnold ET, Thomas LS, et al TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem. 2002;277:20431–20437 [[PubMed]
40. Powers KA, Szászi K, Khadaroo RG, et al Oxidative stress generated by hemorrhagic shock recruits Toll-like receptor 4 to the plasma membrane in macrophages. J Exp Med. 2006;203:1951–1961
41. Li Y, Si R, Feng Y, et al Myocardial ischemia activates an injurious innate immune signaling via cardiac heat shock protein 60 and Toll-like receptor 4. J Biol Chem. 2011;286:31308–31319
42. Wu H, Chen G, Wyburn KR, et al TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007;117:2847–2859
43. Dvoriantchikova G, Barakat DJ, Hernandez E, Shestopalov VI, Ivanov D. Toll-like receptor 4 contributes to retinal ischemia/reperfusion injury. Mol Vis. 2010;16:1907–1912
44. Summers SA, Hoi A, Steinmetz OM, et al TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J Autoimmun. 2010;35:291–298 [[PubMed]
45. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, et al Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest. 2008;118:205–216
46. Yun TJ, Harning EK, Giza K, et al EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity. J Immunol. 2011;186:563–575 [[PubMed]
47. Brunn GJ, Bungum MK, Johnson GB, Platt JL. Conditional signaling by Toll-like receptor 4. FASEB J. 2005;19:872–874 [[PubMed]
48. Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol. 2010;10:712–723 [[PubMed]
49. Vogl T, Tenbrock K, Ludwig S, et al Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13:1042–1049 [[PubMed]
50. Zhou L, Beuerman RW, Chan CM, et al Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. J Proteome Res. 2009;8:4889–4905 [[PubMed]